TLR7型
癌症研究
肿瘤进展
转移
腺癌
生物
Toll样受体
间质细胞
医学
免疫系统
癌症
免疫学
先天免疫系统
内科学
作者
Marion Dajon,Kristina Iribarren,Florent Petitprez,Solenne Marmier,Audrey Lupo,Mélanie Gillard,Hanane Ouakrim,Navas Victor,Vincenzo Di Bartolo,Pierre-Emmanuel Joubert,Oliver Kepp,Guido Kroemer,Marco Alifano,Diane Damotte,Isabelle Cremer
出处
期刊:OncoImmunology
[Informa]
日期:2018-10-11
卷期号:8 (1): e1505174-e1505174
被引量:45
标识
DOI:10.1080/2162402x.2018.1505174
摘要
In non-small cell lung carcinoma (NSCLC), stimulation of toll-like receptor 7 (TLR7), a receptor for single stranded RNA, is linked to tumor progression and resistance to anticancer chemotherapy. However, the mechanism of this effect has been elusive. Here, using a murine model of lung adenocarcinoma, we demonstrate a key role for TLR7 expressed by malignant (rather than by stromal and immune) cells, in the recruitment of myeloid derived suppressor cells (MDSCs), induced after TLR7 stimulation, resulting in accelerated tumor growth and metastasis. In adenocarcinoma patients, high TLR7 expression on malignant cells was associated with poor clinical outcome, as well as with a gene expression signature linked to aggressiveness and metastastic dissemination with high abundance of mRNA encoding intercellular adhesion molecule 1 (ICAM-1), cytokeratins 7 and 19 (KRT-7 and 19), syndecan 4 (SDC4), and p53. In addition, lung tumors expressing high levels of TLR7 have a phenotype of epithelial mesenchymal transition with high expression of vimentin and low abundance of E-cadherin. These data reveal a crucial role for cancer cell-intrinsic TLR7 expression in lung adenocarcinoma progression.
科研通智能强力驱动
Strongly Powered by AbleSci AI